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 God says in his Holy Qur’an to his prophet, 
 
“We shall show them our signs in the utmost horizons [of the universe] 
and within themselves, so that it will become clear to them that this 
[revelation] is indeed the truth. [Still,] is it not enough [for them to 
know] that your Lord is witness unto everything?” 
 
Holy Qur’an: 41:53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my parents and my kids 
  
ABSTRACT 
 
Oligonucleotides (ONs) are short sequences of nucleic acids which may be used in a 
therapeutic context to modulate gene expression. According to their target, ONs can be 
classified into two main classes: antisense ONs which target mRNA and antigene ONs 
that target chromosomal DNA. In order to be pharmaceutically efficient, both kinds of 
ONs have to possess enough stability against degrading enzymes and rapid clearance. 
They must pass the cell membrane, and in some cases the nuclear membrane, and bind 
with enough specificity and high affinity to their target site to successfully exert their 
desired effect. In fact, the use of natural nucleic acids as drugs is hindered by both their 
inherent instability in biological fluids and their highly charged nature, which hampers 
their cellular uptake. Therefore, research in the field of ON-based pharmaceuticals 
focuses on two main strategies: chemical modification of nucleic acids to produce 
analogues with better stability and binding properties, and development of delivery 
systems to further stabilize the ONs and enhance their cellular uptake.  
 
Splice-switching antisense ONs (SSOs) made of phosphorothioate 2’-O-methyl RNA 
are promising therapeutics for several disorders caused by aberrant splicing. However, 
as other ONs, their usefulness is hindered by the lack of efficient delivery. In the first 
study of this thesis, four amino acid modified versions of the well-known polycation 
polyethylenimine (PEI) were evaluated for the formulation and delivery of SSOs. The 
formulations were physically characterized via assessment of their particle size and 
stability and this characterization was then correlated to their splice-correction 
efficiency after transfection into mammalian cells. Tyrosine-modified PEI (PEIY) was 
identified as a successful delivery system for SSOs as shown by splice-correction 
efficiency of 80% measured in HeLa705; a cell-model containing a mutated β–globin 
intron sequence found in β–thalassemia splicing disorder.  
 
In the second study, a new cell penetrating peptide (PepFect 14) was developed and 
investigated for the formulation and delivery of SSOs using cell-models for two 
splicing disorders; β-thalassemia and Duchenne muscular dystrophy. The feasibility of 
incorporating this delivery system into solid formulations via solid dispersion technique 
was also demonstrated. The formed solid formulations were as active as the freshly 
  
prepared nanocomplexes in solution even when stored at elevated temperatures for 
several weeks. 
 
In the third study, PepFect 14 was evaluated for the formulation and delivery of another 
kind of ONs: short interfering RNA (siRNA) in different cell lines. RNA interference 
effect was obtained at low siRNA doses with a unique kinetic profile. Solid 
formulations were then prepared and assessed for their stability in gastric conditions. 
PF14/siRNA solid formulations showed marked stability after incubation with 
simulated gastric fluid, which is extremely acidic and contains proteolytic enzymes. 
 
The fourth study of this thesis addressed design optimization of the newly developed 
antigene ON, Zorro-LNA (Zorro). Here, double-strand invasion was proven as the 
mechanism by which Zorro binds to duplex DNA. The original Zorro, targeting both 
strands of the DNA duplex, was made of two ONs connected via a 7-nucleotide linker. 
In this report, the possibility to synthesize Zorro as a bi-directional single-stranded ON 
was investigated, thus reducing the size, facilitating the design and improving Zorro 
efficiency.  
 
In conclusion, this thesis has dealt with developing formulation strategies for two 
different types of ON-based pharmaceuticals; SSOs and siRNA. Optimizing the design 
of Zorro LNA as an antigene ON has been also investigated. These findings may 
represent a step in the development of ON-based drug products as a new class of 
therapeutics. 
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1 INTRODUCTION 
 
1.1 GENE THERAPY 
The concept of gene therapy is based on the use of nucleic acids as drugs for restoring, 
shutting down or modulating a specific cellular function. In contrast to conventional 
drugs that often focus on the protein level-treatment of diseases, gene therapy provides 
a treatment rather upstream at the molecular level of gene expression i.e. on the DNA 
and RNA levels. It was not until the late 1980s, after the invention of recombinant 
DNA technology and the development of retroviral vectors, that the first human trials 
for gene therapy were conducted. In 1990, the first successful gene therapy-based 
clinical trial was reported when the adenosine deaminase (ADA) gene was transferred 
into T-cells of patients with severe combined immunodeficiency (SCID) using a 
retroviral vector (1). Now and after two decades of intensive research in the gene 
therapy field, scientists have proven that they can treat at least half a dozen rare genetic 
diseases (Table 1), and that early trials are beginning to find benefits for common 
diseases as well, including HIV, leukemia, and heart diseases (2,3).  
 
 
 
 
 
 
 
 
According to the desired therapeutic effect, gene therapy involves two main 
approaches. The first approach is the restoration of lost gene function via gene delivery 
using viral vectors or plasmid DNA. The second approach is the silencing or 
modulation of gene function using shorter sequences of nucleic acids known as 
“Oligonucleotides” (ONs). It is also worth saying that successful gene therapy basically 
relies on not only the nucleic acid material to be inserted but also the vector used for its 
delivery (4). The concept of using ONs for gene modulation or silencing, as well as the 
optimization of delivery vectors for their successful entry into cells represent the main 
focus of this thesis. 
Disorder            Disease Type       Patients       first publication
benefiting      year
Table 1. Some gene therapy successes over 
the last decade.
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1.2 OLIGONUCLEOTIDE-BASED PHARMACEUTICALS 
 
 
 
 
 
 
 
 
 
Oligonucleotide-based pharmaceuticals constitute a new and interesting class of drugs 
that is rapidly increasing in size and importance. ONs are defined as short sequences 
(ranging from 8-50 bases) of nucleic acids or nucleic acid analogues that can be used 
for silencing of targeted genes or modifying their expression pattern. ONs can be 
classified into two main classes according to their target: antisense ONs which target 
mRNA and antigene ONs that target chromosomal DNA (5,6) (Figure 1).  On their way 
to exert the desired effects, both kinds of ONs are confronted by many obstacles. They 
must resist the degradation by serum enzymes and the rapid clearance, they need to 
reach their target site of action and successfully pass the cell membrane, and in some 
cases, the nuclear membrane too. In addition, antigene ONs are faced by even more 
challenges that hamper their action represented in finding their way through chromatin 
complex structure in order to finally recognize their target sequence within 
chromosomal DNA and specifically bind to it (7). This may explain the fact that 
antisense ONs are much described in literature and more explored than ONs working 
via the antigene approach.  
 
Research in the field of ON-based pharmaceuticals aims at producing ONs with better 
stability, permeability and binding efficiency (8). Two main strategies have been 
addressed for achieving these purposes. First strategy is the chemical modification of 
nucleic acids in order to improve the ONs pharmacokinetic and pharmacodynamic 
properties. The second approach is the development of delivery systems to enhance the 
cellular ON uptake. Each of these two approaches will be discussed in its own section 
under this “Introduction”. To start with, antisense and antigene strategies and some of 
their sub-categories will be described in detail. 
antigene
ON
siRNA
Classical antisense ON 
(mRNA-degrading)
Splice-switching
ON
Non mRNA-
degrading
antisense ON
Figure 1. Illustration of most classes 
of ”ON-based Pharmaceuticals” according 
to their mechanism of action [Modified from (162)].
Detailed description is found in the text below
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1.2.1 ANTISENSE ONs 
In 1978, Paul Zamecnik and Mary Stephenson reported the first experiments on 
antisense mechanisms of gene silencing, using short synthetic antisense ONs to inhibit 
replication of the Rous sarcoma virus by binding and blocking the action of 35s RNA 
(9). More recently, the antisense concept was further enriched and broadened by the 
discovery of RNA interference and of the ability to activate this process using 
exogenous short interfering double-stranded RNAs (siRNAs) (10,11). Currently, 
multiple approaches are available for employing ONs to influence the extent and 
pattern of gene expression via working on the mRNA level of the gene. Antisense ONs 
bind to their target RNA through Watson-Crick base-pairing and consequently 
modulate the function of the targeted RNA. In fact, antisense ONs represent a 
promising drug platform that has the potential to target, in a selective manner, all RNAs 
in a cell. They can exert their effect either by degrading mRNA (mRNA-degrading 
antisense ONs) or without degrading mRNA (mRNA non-degrading antisense ONs) 
(12). The mRNA-degrading ONs include classical antisense ONs, siRNAs, RNA-
cleaving ribozymes and microRNAs. ONs belonging to the mRNA non-degrading class 
work mainly via steric blocking. Examples representing this class include ONs that 
arrest mRNA translation and ONs that modulate the pre-mRNA splicing patterns. 
Selected members representing both categories are herein described in details. 
 
1.2.1.1 CLASSICAL ANTISENSE ONs 
This class is, in fact, the best understood class of antisense ONs, accounting for the 
majority of drugs in development. Classical antisense ONs are single-stranded DNA 
ONs that work through an RNase H-dependent cleavage mechanism. RNase H is a 
family of enzymes present in all mammalian cells that mediates the cleavage of the 
RNA in an RNA-DNA hetero-duplex. Human cells contain two types of RNase H: 
RNase H1 and RNase H2 and both enzymes are thought to play a role in DNA 
replication and repair (13). RNase H1 is the enzyme responsible for mediating the 
target RNA cleavage directed by antisense ONs containing five or more consecutive 
DNA nucleotides (14). The RNase H mechanism has proven to be a robust antisense 
mechanism and is broadly exploited as both a research tool and a potential human 
therapeutic. In 1998, Vitravene® (Fomiversen sodium) by ISIS Pharmaceuticals was 
the first, and so far only, antisense ON approved by FDA. Vitravene® is a classical 
antisense ON that is administered intravitrealy for the treatment of retinitis induced by 
cytomegalovirus in HIV patients (15). Other drugs are now in advanced phases in 
 4 
clinical trials such as Oblimersen sodium; a systemic-acting classical antisense ON 
developed by Genta Pharmaceuticals and administered by IV infusion for treatment of 
cancer via targeting the Bcl-2 mRNA (16). 
 
1.2.1.2 SHORT INTERFERING RNAs (siRNAs) 
They are ONs that work through another RNA cleavage mechanism known as RNA 
interference (RNAi). In fact, RNAi is a naturally occurring mechanism in cells used for 
destroying double-stranded (ds) RNA. This mechanism was first noticed in petunias, 
when plant biologists attempted to deepen the flowers’ purple color by introducing a 
pigment-producing gene. Instead of intensifying the color, the gene suppressed it and 
the resulting flowers had white patches or were completely white. A few years later, in 
1998, RNAi was recognized by Fire and Mello when they injected a dsRNA into 
C.elegans worms which led to the specific down-regulation of the gene including a 
sequence similar to that of the dsRNA (17). For this great discovery of the RNAi 
mechanism, the two scientists were awarded the “Nobel Prize in Physiology and 
Medicine” in 2006. In 2001, the proof of principle study, by Elbashir and coworkers, 
showing that exogenous siRNA could achieve sequence-specific gene down-regulation 
in mammalian cells, marked the birth of siRNA therapeutics (11).  
To briefly describe the RNAi pathway: it is initiated by  
dsRNA which is cleaved by the dicer enzyme into  
21-28 nucleotide siRNA duplexes. These duplexes are then  
transferred to a protein complex termed the pre-RISC loading  
complex (RNA Induced Silencing Complex) which contains  
the enzyme Argonaute 2 (Ago 2) (18,19). The pre RISC  
complex then separates the two strands and an active RISC  
complex containing only the guide (antisense) strand is  
produced (20). The active RISC complex recognizes  
the target mRNA, the guide strand binds via base-base  
complementarity to it and finally the target mRNA is  
degraded by the enzyme Ago 2.  
Exogenously-delivered siRNA enters this pathway  
downstream of Dicer (Figure 2).  
 
 
Cleavage by Dicer
Assembly into RISC
Long dsRNA
siRNA
Target mRNA
recognition
mRNA 
cleavage
Guide strand loading 
and active RISC formation
Figure 2. The RNAi pathway 
and siRNA mechanism of action
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What makes the siRNA approach appealing is that the cleavage of target mRNA occurs 
in a catalytic manner, thus, lower doses are required to achieve gene down-regulation 
compared to other antisense technologies. That is why intensive research has been 
carried out to develop siRNA-based pharmaceuticals and a number of them are 
currently in advanced clinical testing phases (21-25). One example is the ALN-VSP, by 
Alnylam Pharmaceuticals, which is siRNA in liposomal formulation, designed to target 
the vascular endothelial growth factor (VEGF) mRNA as a way for treatment of 
primary and secondary liver cancers (24). 
 
1.2.1.3 SPLICE-SWITCHING ANTISENSE ONs 
Splice-switching ONs (SSOs) are antisense ONs that bind to pre mRNA, without 
degrading it, in order to modulate its splicing pattern. To understand their mechanism 
of action and their use as pharmaceuticals, some basic facts about the process of pre-
mRNA splicing will be introduced. 
 
1.2.1.3.1 SPLICING AND ALTERNATIVE SPLICING. 
Pre-mRNA splicing is an essential post-transcriptional process that occurs in the 
nucleolus of the cell. In this process, pre-mRNA introns are excised and the exons are 
joined in order to form a typical mRNA to be transported to the cytoplasm and finally 
translated into protein.  Frequently, a single pre-mRNA transcript can be spliced to 
produce multiple mRNA variants which in turn will be translated to different proteins. 
This process is known as “Alternative Splicing” (26). Factors such as tissue, stimulus 
and developmental stage were proven to control the process of alternative splicing (27). 
Interestingly, recent studies indicate that 70% of human pre-mRNA undergoes 
alternative splicing. This is most probably the major source for protein diversity 
generating the huge number of proteins present in human cells which greatly exceeds 
the number of their encoding genes (28).  
 
Splicing and alternative splicing depend on essential sequence elements, known as the 
“splicing code”, in pre-mRNA (29). The splicing code is briefly represented in: 5’ and 
3’ splice sites (at the exon-intron junctions), branch point, polypyrimidine tract and 
additional splicing regulatory elements that exist within both exons and introns known 
as exonic/intronic splicing enhancers and exonic/intronic splicing silencers. 
Components of the basal splicing machinery bind to splice site sequences and promote 
assembly of the multi-component splicing complex known as, the spliceosome that 
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catalyzes the removal of introns and joining of exons (30). Alternative splicing can be 
performed through several different pathways (31) such as those showed in Figure 3.  
 
 
 
 
 
 
1.2.1.3.2 ABERRANT SPLICING AND DISEASES 
It has been estimated that up to 50% of human genetic diseases arise from mutations 
that affect splicing (32). Several serious genetic disorders including β-thalassemia , X-
linked agammaglobulinemia (33) , cystic fibrosis, atherosclerosis, muscular 
dystrophies, spinal muscle atrophy and many types of cancers are associated with 
mutations that alter the splicing pattern (34). One of the first described splicing 
mutations was found in β-thalassemia patients, where point mutations in intron 1 or 2 
of β-globin pre-mRNA creates an apparent 5’ splice site which concomitantly activates 
a cryptic 3’ splice site. This in turn leads to inclusion of a part of the intron (a pseudo 
exon) encoding for stop codon in the mRNA transcript and thus formation of truncated 
non-functional β-globin protein (35). Several examples of this pathogenic mechanism 
have been shown for diseases such as cystic fibrosis, ataxia telangiectasia, 
neurofibromatosis type I and many inherited metabolic diseases (36-39). The well-
known muscular disorders “Duchenne muscular dystrophy” (DMD), characterized by 
progressive degenerative myopathy, and its milder allelic disorder, Becker muscular 
dystrophy (BMD), are both caused by mutations in the dystrophin gene. In DMD, the 
mutations result in premature termination of translation and thus lack of dystrophin 
protein, while in the milder form (BMD), a mutation within a regulatory sequence for 
splicing leads to in-frame skipping of one or more exons resulting in the formation of a 
truncated, partially functional protein (40). 
 
1.2.3.1.3 ANTISENSE ONs FOR SPLICE-SWITCHING 
A therapeutic platform that has gained increasing attention since the initial discovery in 
1993 is the use of antisense ONs to modulate splicing patterns as a way for the 
treatment of aberrant splice disorders (35). Antisense SSOs bind by complementarity to 
a selected region in the pre-mRNA and inhibit by steric hindrance the recognition of 
that region by the splicesomal machinery, thus switching the splicing towards the 
Exon 1
Exon 2
Exon 2
Exon 1
Exon 1 Exon 2
Exon 1
Exon 2
Exon 2
Exon 1
Exon 1 Exon 2
Exon 1
Exon 2
Exon 2
Exon 1
Exon 1 Exon 2
Exon 3Exon 1
Exon 3Exon 1 Exon 2
Exon 1 Exon 3
Exon 2a b c d
Figure 3. Examples of alternative pre-mRNA splicing pathways. (a) use of alternative 5' splice sites; 
(b) use of alternative 3' splice sites; (c) intron retention and (d) a choice to include or skip an exon
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desired pattern (Figure 4). Hundreds of studies have investigated the clinical interest of 
this technology (41-43) therefore; two examples of targets showing great advance in 
clinical trials will be further described.  
 
β-thalassemia is a genetic blood disorder characterized by a deficiency of β-globin 
chains, leading to the reduction or absence of adult haemoglobin and thus excessive 
destruction of red blood cells. It is a fairly common disease and its current therapy 
consists of frequent blood transfusions combined with iron chelation treatment. The 
only cure, bone marrow transplantation, is limited by the scarcity of suitable 
histocompatible donors (44). The use of antisense SSOs that can block the intronic 
cryptic splice site has greatly succeeded in correcting the aberrant splicing back to 
normal in erythroid cells restoring β-globin expression (45). Moreover, repair of β-
globin pre-mRNA rendered defective by the same splicing mutation was accomplished 
in vivo in a mouse model of β-thalassemia via systemic delivery of antisense SSO 
conjugated to a peptide (46).  
 
 
 
 
 
 
 
DMD is a severe X-linked monogenic neuromuscular disorder that affects 1 in 3500 
boys worldwide with no radical cure yet (47). SSOs have been applied to promote exon 
skipping as another mechanism by which splicing pattern can be modulated. In DMD, 
this approach was validated using SSOs that blocked pre-mRNA splicing elements, 
thereby excluding the mutation-containing exon and restoring the reading frame in 
DMD transcripts thus converting the disease to the milder Becker form. Exon skipping 
SSOs have been successfully evaluated both in cells and in vivo using a DMD mouse 
model; namely “the mdx mouse” where a non-sense mutation in exon 23 leads to 
premature termination during translation (48). Interestingly, two SSOs targeting 
mutations in exon 51 for treating the same disease and developed by AVI BioPharma 
and Prosensa (together with GlaxoSmithKline) are currently in human clinical trials 
(phases 1 and 2) in DMD patients treated locally (49,50) and more recently 
systemically (51).  
a b c
Figure 4. Overview of some of the reported antisense applications for splicing modulation. SSOs
(thick black bars) have been used to (a) revert aberrant splicing caused by activated pseudoexons, 
(b) exclude exons with pretermination code (PTC) mutation, (c) exclude one or more exons 
to restore the open reading frame.
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1.2.2 ANTIGENE ONS 
The antigene strategy is based on the sequence-specific targeting of the chromosomal 
ds DNA, in this way acting upstream of the RNA antisense approach. In fact, 
developing ONs for antigene purpose confronts several challenges (52). Compounds 
must be able to enter cells, pass into the nucleus, and bind chromosomal DNA with 
high specificity. Binding must occur in spite of the already existing base-pairing at the 
target site and complexation of the genomic sequence with histones, transcription 
factors, and other DNA binding proteins. Once bound, the association of an oligomer 
with the chromosome must be sufficiently stable and long-lasting to affect gene 
expression. These challenges make recognition of DNA more complex than recognition 
of mRNA and overcoming them requires much investigation on the biochemical 
properties of nucleic acids and their chemically modified analogues forming the 
antigene ONs. Ten years after James Watson and Francis Crick published their model 
of the DNA double helix (53), Karst Hoogsteen reported his finding of another mode of 
binding that also exists, although rarely, forming a triple helix in chromosomal DNA 
(54).  Antigene ONs were developed to bind to ds DNA either via the Hoogsteen or the 
Watson-Crick mode of binding (Figure 5).  
 
 
 
 
 
 
1.2.2.1 BINDING VIA HOOGSTEEN 
In the half-century since the first triple helical structures in RNA were reported  (55), 
significant progress has been made in developing triplex forming ON (TFOs) to bind to 
the major groove of ds DNA and form a triple helix. TFOs may serve as antigene ONs 
that bind to homopurine stretches in the major groove of duplex DNA via Hoogsteen 
hydrogen bonds formed between the base of the third strand and the purine base of the 
duplex DNA (56). The presence of divalent cations Mg2+, Ca2+ and Zn2+ as well as 
naturally occurring polyamines such as spermine and spermidine were found to help 
stabilizing the triple-helix, by reducing the electrostatic repulsion among the three 
phosphate backbones (57). 
Figure 5. Antigene ONs binding to 
chromosomal DNA via Hoogsteen 
(blue ON) or Watson-Crick (red ON) 
modes of binding. Hoogsteen binding occurs in the major groove of DNA and known to cause little
distortion as compared to the Watson-Crick binding, which mostly involves invasion to the duplex 
DNA. Details are found in the text.
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Triplex formation occurs in two motifs, distinguished by the orientation of the third 
strand with respect to the polypurine strand in the duplex DNA (Figure 6). Generally, 
pyrimidine-rich TFOs bind in a parallel manner, while purine-rich TFOs bind in an 
anti-parallel orientation (58). In the pyrimidine motif, thymines or protonated cytosines 
of the TFO bind to A:T or G:C Watson-Crick base pairs, respectively, forming the 
canonical base triads T:AT and C+:GC. This kind of binding can only occur under 
acidic conditions, since N3 protonation of the third strand cytosine is required for 
proper Hoogsteen binding to the N7 of duplex guanine. On the other hand, the purine-
rich motif binds to DNA in an antiparallel direction via reverse Hoogsteen bonds to 
form the base triads G:GC and A:AT. In contrast to the pH requirement of pyrimidine-
rich TFOs, effective binding for the purine TFOs requires no protonation, allowing 
them to bind at neutral pH. However, the guanines in purine-rich oligonucleotides were 
shown to form G-quartet structures in physiologic concentrations of K+ (59). This kind 
of intermolecular complexes could significantly reduce the bioavailability of TFO 
molecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TFOs have been used to inhibit transcription of some endogenous genes in vitro and in 
cell cultures; however, the efficiencies have not been that great. There are several 
drawbacks in the TFO technology limiting its use for in vivo gene down-regulation. 
TFOs are sequence-restricted since they are only able to bind to homopurine stretches 
................ ................
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3’5’
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Pyrimidine-rich TFO Purine-rich TFO
3’ 5’5’ 3’
Figure 6. Triplex binding in the purine rich and pyrimidine rich TFOs, [Adapted from (58)].
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in DNA. While triplex formation by TFOs is straightforward under controlled 
conditions of pH and ion concentrations in vitro, the physiological environment in 
living cells presents substantial obstacles as shown in the low pH required for cytosine 
protonation and the low concentration of K+ to avoid G-quartet formation. Moreover, 
there is evidence that duplex DNA undergoes helical distortions upon TFO binding 
which could explain the interruption of triplex formation by the nucleotide excision 
repair machinery in the cell (60) 
 
Many strategies have been investigated in order to optimize the use of TFOs for in vivo 
gene regulation (61,62). Nucleic acids chemical modification, which will be discussed 
in its own section, has been applied as a main and important one of those strategies 
(63,64). Polycations grafted with copolymers such as polylysine-graft-dextran have 
been shown to form a stable association with TFOs which greatly alleviated the 
electrostatic repulsion between the TFO and duplex DNA and also allowed triplex 
formation even at physiological pH (65,66). It has been recently shown that using 
Twisted Intercalating Nucleic Acids (TINA) has a great stabilization effect on the 
triplex (67). Inserting TINA bases in a TFO has been shown to help avoid the K+ 
induced self aggregation problem that usually happens in G-rich TFOs (68).  
 
1.2.2.2 BINDING VIA WATSON-CRICK 
ONs that bind to ds DNA via Watson-Crick hybridization mechanism constitute a 
relatively new and appealing category of antigene drugs. Opposite to TFOs, ONs 
belong to this class do not require any sequence restriction since, in theory; they can be 
designed to target any DNA stretch in the genome. Binding by these ONs is performed 
via invasion into duplex DNA strands: double-strand invasion (DSI). As already 
referred to in the antisense ONs and TFOs, nucleic acid modifications are, herein as 
well, required for the sake of getting antigene ONs with good hybridization and 
efficient DSI properties into chromosomal DNA. Peptide nucleic acid (PNA) and 
locked nucleic acid (LNA) are the two most common nucleic acid analogues used for 
making ONs of this class. DSI properties for PNA-based antigene ONs have been 
clearly investigated (69). DSI associated to transcription inhibition was first reported 
for a linear PNA-based ON targeted against the CAG triplet of the androgen receptor 
gene (70). PNA was also found to target specific c-myc gene regions (71). Regarding 
LNA, Corey and coworkers have used linear LNA-based ONs to target progesterone 
receptor gene transcription start sites leading to gene down-regulation in cell culture 
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(52,72). However, the actual mechanism of LNA-based antigene ONs was not 
conclusively demonstrated.  
 
In our lab, we have developed a new LNA-based antigene drug designated “Zorro-
LNA”. The original Zorro-LNA (Zorro) consists of two LNA/DNA mixmer ONs 
attached to each other through a 7-nucleotide (7-nt) complementary linker region. One 
of the ONs is constructed to bind to the coding strand of DNA and the other to the 
template strand. It was observed that Zorro can successfully bind to DNA duplexes and 
inhibit gene transcription on the plasmid level (73). Moreover, when Zorro was 
microinjected into cells stably transfected with the target site-containing reporter gene, 
it also mediated blocking of gene expression (74).  
 
 
 
 
 
In the fourth paper of the papers constituting this thesis, DSI was proven as the 
mechanism by which Zorro binds to ds DNA (75). This was the first proof conclusively 
demonstrating that an LNA-based antigene ON could strand invade into duplex DNA 
and, as shown in the paper, the Zorro shape was a requirement for achieving DSI. In 
early 2011, the Zorro concept was used by Hoffman and coworkers where they 
delivered Zorros into human fibroblasts by microporation to down-regulate the NF1 
gene expression (76). Nowadays, in our lab, further optimization of both the design and 
the formulation of Zorro antigene ONs is currently undertaken for the aim of targeting 
genes in the genomic DNA context.  
 
 
Figure 7. Schematic representation of the original 
”Zorro-LNA” concept. Two LNA/DNA mixmer ONs 
are binding simultaneusly to the sense and antisense 
strands of DNA. The 2 ONs are connected via 
complementarity in a 7-nt linker region.
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1.3 CHEMICALLY MODIFIED NUCLEIC ACIDS 
(NUCLEIC ACIDS ANALOGUES) 
Unmodified DNA and RNA are inherently unstable molecules in biological systems, 
based on the degradation effect by nucleases that cleave the phosphodiester linkage. 
This instability hinders the use of natural unstabilized nucleic acids as drugs because 
they are degraded before they have a chance to reach their target sites of action. In 
addition, the pharmacokinetics of RNA and DNA make them unacceptable systemic 
pharmaceuticals because they are weakly bound to plasma proteins thus rapidly filtered 
by the kidney and excreted into urine. Binding to intracellular DNA or RNA targets, 
which are known to be highly structured, requires ONs with not only high affinity but 
also high specificity to avoid the adverse effects resulting from the off-target binding. 
Collectively, the intrinsic binding affinity and pharmacokinetics of natural ONs are 
insufficient for their use as systemic drugs (12). Therefore, research dealing with the 
chemical modification of nucleic acids has got great attention among work done in the 
field of ON-based pharmaceuticals. These modifications can be classified according to 
their location within the nucleic acid chain. Nucleic acid analogues can be synthesized 
via chemical modifications in the phosphate backbone, the sugar, the sugar-phosphate 
backbone and in the heterocycle (nucleotide base). Examples representing each class 
will be discussed in this section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Examples of the most 
common chemical modifications 
used in ON-based pharmaceuticals,
[Adapted from (12)]. Details are found 
in the following text. 
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1.3.1 PHOSPHATE BACKBONE MODIFICATIONS  
Since the phosphodiester linkage in natural nucleic acids is significantly susceptible to 
degradation by nucleases, the ON backbone presents the first target for improvement 
with chemical modification. Consequently, extensive research has focused on efforts to 
find backbone modifications that increased the nuclease resistance with maintaining or 
even improving the affinity and specificity to the target. Phosphorothioate (PS)-
containing ONs were one of the earliest backbone modifications where one of the non-
bridging phosphate oxygen atoms is replaced with a sulfur atom (77). This substitution 
provides the ONs with several properties that are crucial for their use as systemic drugs. 
First, and most important, it greatly increases the resistance to nucleolytic degradation; 
thus the ON will possess sufficient stability in plasma, tissues and cells and avoid 
metabolism before reaching to its target. Second, PS modification confers a substantial 
pharmacokinetic benefit by increasing the binding to plasma proteins; thus increasing 
the ON circulation residence time and preventing the rapid clearance, which in turn will 
improve the ON availability to the different tissues (78).  Third, PS-modified ON is still 
able to elicit mRNA cleavage via RNase H activation therefore, it can be used as 
antisense ON working via the mRNA degrading mechanism. Most antisense ONs that 
are in clinical trials are PS-modified ONs, also so called “first generation antisense 
drugs”, and the only ON approved by FDA (Vitravene®), as mentioned earlier, is a 
21mer PS-modified RNA ON (15). The major disadvantage with PS-modified ONs is 
their unspecific binding to plasma proteins which might raise toxicity concerns (79,80). 
Another problem is their reduced affinity to their target RNA; however this is 
compensated by their high binding specificity. Nevertheless, PS remains the most 
successful modification to date in ON-based pharmaceuticals. They are used for 
antisense ONs working by different mechanisms mainly those working by RNase H 
activation and ONs used for splice modulation (81-83) . 
 
1.3.2 SUGAR MODIFICATIONS 
The two most common and extensively studied approaches for chemically modifying 
the nucleic acid sugar are via substitution on the 2’-position or locking of the sugar 
ring. Modifications on the 2’-position of the sugar moiety, also known as “second 
generation antisense ONs”, were shown to provide the ON with more affinity and less 
toxicity compared to the PS-modification described before. Furthermore, the proximity 
of the 2’-substituent to the 3’-phosphate in an ON generally makes 2’-substitued ON 
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show higher nuclease resistance (12). Unfortunately, the 2’-modified ONs do not have 
the ability to activate the RNase H degradation of mRNA. This limitation has been 
minimized by use of a gapmer strategy, where a block of 2’-modified residues used for 
increasing the stability and affinity is flanking a central unmodified DNA region of the 
ON. Otherwise, 2’-modifications have been extensively used in synthesis of siRNAs 
and SSOs where RNase H-mediated mRNA degradation is not required for 
accomplishing the effect.  
 
2’-O-methyl is the most well-known example representing this category. It has been 
used for making many splice-switching ONs, currently in clinical trials, such as PRO-
051 used for DMD treatment (84,85). Among the 2’-class of modifications, 2’-fluoro 
has shown the highest binding affinity for target RNA (86). It has been employed by 
Alnylam Pharmaceuticals in design of siRNAs providing duplexes with increased 
stability and potency (23). A third example is the 2’-O-methoxyethyl (MOE) 
modification, which is currently the most advanced of the 2’-modified series and has 
entered clinical trials for multiple indications. It increases Tm by about +2 °C per 
modification and increases resistance to nucleases. It also appears to reduce the 
nonspecific protein binding which can reduce toxicities (87). This modification has 
been mainly pioneered, by ISIS Pharmaceuticals, in the synthesis of many therapeutic 
antisense ONs indicated for cardiovascular, metabolic, inflammatory and 
neurodegenerative disorders as well as cancer and currently in clinical trials (87-89). 
Some examples are Mipomersen (phase III) for treatment of hypercholesterolemia via 
targeting of apolipoprotein B-100 mRNA (90) and OGX-011 (phase III) targeting 
clusterin mRNA for prostate cancer treatment (91).  
 
The sugar modification showing the largest known improvement in binding affinity has 
been made via locking the sugar ring in the well-known nucleic acid analogue: “locked 
nucleic acid” (LNA) (92). In LNA, a methylene bridge is introduced between the 2’-O 
and 4’-C of the ribose sugar ring. The resulting conformationally restricted, bicyclic 
moiety leads to higher stability of duplexes formed with complementary DNA and 
RNA sequences (93). LNA ONs do not support RNase H, thus a gapmer strategy must 
be employed for ONs designed to work via this mechanism. LNA-modified antisense 
ONs, similar to 2’-MOEs, have been exploited for numerous indications such as cancer 
and hepatitis C (94). Santaris Pharma has developed many LNA antisense ONs such as 
Miravirsen, also known as “SPC3649” (phase II) for the potential treatment of Hepatitis 
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C via down-regulating miRNA 122 (95). LNA ONs have shown success in altering 
splicing both in cell cultures and in mouse models (96). In the antigene field, LNA 
substituted TFOs have shown an increased triplex thermostability and better binding 
affinity even at neutral pH, which is important for the homopyrimidine type TFO (97). 
Linear LNA ONs binding via Watson-Crick were tested in cell cultures (52).   
 
1.3.3 SUGAR-PHOSPHATE BACKBONE MODIFICATIONS 
This type of modifications is done via replacement of the sugar-phosphate backbone 
with an isostere. One of these lead to the phosphorodiamidate morpholino ONs 
(PMOs), which have a morpholino ring as a replacement of the furanose sugar, with a 
phosphorodiamidate linkage instead of the phosphodiester backbone. Because of the 
phosphorodiamidate linkage, PMOs are neutral. These modifications are nuclease 
stable; however they do not activate RNase H. PMOs have been exploited in steric 
blocking mechanisms such as splice modulation and translation arrest (98). For splice 
switching, AVI-4658 (phase II) is a PMO developed by AVI BioPharma for systemic 
treatment of DMD (99).  
 
Peptide nucleic acids (PNAs) are a completely different class of ON analogues that 
contain a peptide replacement for the sugar phosphate backbone (100). The uncharged 
nature of PNA molecules highly decreases the electrostatic repulsion in its hybrids with 
DNA or RNA, thus increasing the duplex thermal stability. However, PNA ONs are 
poorly water soluble and do not readily cross cell membranes, which hampered their 
pharmaceutical development. These limitations have been addressed by conjugation 
with peptides to improve their cellular uptake (101). PNA-peptide conjugates have 
been used as SSOs for DMD treatment (102). As stated earlier, PNA has also the ability 
to strand-invade into a duplex DNA. 
 
 
1.3.4 HETEROCYCLE (NUCLEOTIDE BASE) MODIFICATIONS 
Modification in the heterocycle has focused mainly on increasing the binding affinity 
for complementary target sites (103). The most common example in this class is the 5’-
methylcytosine substitution which is used instead of natural cytosine in 
homopyrimidine TFOs. 5’-methylcytosine has a higher pKa value which facilitates the 
TFO binding in physiological conditions. Another replacement for cytosine is the 
pseudoisocytosine which also remains protonated in physiological conditions, and is 
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particularly effective in TFOs containing consecutive cytosines. In fact, a TFO with 
pseudoisocytidine substitutions has been shown to target the human β-globin gene in 
living cells, while the equivalent TFO with 5’-methylcytosine substitution did not form 
stable triplexes at physiological pH (104).  
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1.4 FORMULATION OF ONs 
Numerous modifications, as discussed earlier, have been proposed to improve the 
pharmacological properties of ONs, for example to improve their metabolic stability or 
their affinity, or to increase their selectivity in target recognition. However, free ONs 
are not taken up efficiently by most cell types unless associated with nucleic acid-
delivery vectors. ONs, made of natural and/or chemically-modified nucleic acids, are 
hydrophilic drugs with low permeability and as such categorized under “class III drugs” 
in the biopharmaceutical classification system (105). This is due to the highly dense 
charge distribution on nucleic acids as well as most of the nucleic acid analogues, 
which ON drugs are made of. In fact, the major obstacle to clinical application of ONs 
remains their poor cellular uptake. Recently, a number of developed chemically-
modified ONs have been proven efficient upon intravenous injection. However, the 
lack of a targeted carrier system means the usage of large amounts of material, turning 
this treatment into a highly expensive approach; in particular if the goal is to compete in 
the market with other treatments. Efficient delivery systems should also be able to 
compact ONs into well-defined particles that are stable upon storage. Therefore, several 
viral and non-viral vectors have been developed to improve ON delivery. In this 
section, a number of non-viral delivery systems that are used for ON formulation will 
be described. 
 
1.4.1 LIPID-BASED DELIVERY SYSTEMS 
Lipid-based delivery systems for nucleic acids are the most extensively studied 
systems, as shown by the great number of commercially available lipid-based 
transfection reagents. Two main categories of lipid-based delivery systems have been 
developed. The first was by chemical conjugation between ONs and lipid molecules 
such as cholesterol, phospholipids or other alkyl chains with the aim of increasing the 
lipid solubility of nucleic acids in order to improve their cell membrane permeability  
(106,107). However, using this strategy, although greatly improving the intracellular 
delivery, is not optimal in providing the ONs with enough protection against serum 
nucleases in vivo. The non-covalent ON/ lipid complexes form the second and most 
successful set of lipid-based ON delivery systems. According to the charge of the lipid, 
two subcategories can be here described. ONs can be encapsulated into the aqueous 
core of liposomes made mainly of anionic and or zwitter-ionic lipids. Oppositely, 
cationic lipids can be directly complexed with ONs and these kinds of systems are 
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called “lipoplexes” and sometimes referred as to “cationic liposomes” (108). The later 
is the most successful delivery system in vitro and offers the most commercially 
available systems. Cationic lipids are made up of a cationic head group attached by a 
linker to a lipid hydrophobic group. Lipoplexes are formed via electrostatic interaction 
between the positively charged head group and the negatively charged nucleic acids 
(109). Avoiding the tedious step of encapsulating the ON into liposomal formulation, 
lipoplexes are formed by simple mixing of its components. Examples of typical 
cationic lipids that can be used for this purpose are DOTMA, DOTAP, DC-cholesterol, 
and DOGS. Because most liposomal formulations are internalized by endocytosis, 
during which they would fuse with lysosomes, fusogenic lipids such as DOPE are used 
to enhance the endosomal escape (110). Lipid-based systems are yet not developed for 
in vivo delivery. Because of their aggregation and non-specific binding to plasma 
proteins, they are often toxic and eliminated from the blood by the reticulo-endothelial 
system (RES), with a relative immuno-stimulatory effect (111). PEG-lipid derivatives 
have been employed to prevent the aggregation, stabilize and prolong the circulation 
time of liposomal formulation (stealth liposomes) (112). 
 
 
1.4.2 POLYMER-BASED DELIVERY SYSTEMS 
Cationic polymers have been successfully studied for their ability to deliver nucleic 
acid materials into the cells. They can be bound to nucleic acids (mainly DNA) via 
electrostatic interaction to form a particulate system known as “polyplex” (113). The 
chemical structure of polycations comprises repeated units that can be easily 
manipulated by chemical modification to improve the physical and biological 
properties of the resultant polyplexes. However, opposed to cationic lipids, they are 
devoid of a hydrophobic domain, and therefore cannot fuse/destabilize the endosome 
by direct interaction with the endosomal membrane. The first-generation cationic 
polymers, exemplified by poly-L-lysine (PLL), were quite inefficient in terms of 
endosomal escape and transfection efficiency. Co-transfection with endosomolytic 
agents or introducing histidine moieties into its backbone was required in order to 
accomplish successful transfection with PLL (109). PLL polyplexes were also rapidly 
cleared from the circulation, thus addition of PEG has been investigated for 
prolongation of their circulation half-life. On the other hand, second generation cationic 
polymers such as polyethyleneimine (PEI) and polyamidoamine (PAMAM) can 
mediate endosomal disruption by acting as “proton sponges”. Among the polycations 
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currently used for nucleic acid delivery, PEI has the most prominent position (114,115). 
PEI can exist as linear or branched polymer and in varying molecular weights. Every 
three atoms is an amine making PEI a highly protonable polymer, which can induce a 
buffering effect over a wide range of pH. This buffering property enabled PEI to escape 
from the endosomes due to the proton sponge effect (Figure 9) (109). Briefly, 
endosomal membranes possess an ATPase enzyme that actively transports protons 
from the cytoplasm into the vesicles leading to its acidification. Polymers that contain a 
large number of secondary and tertiary amines such as PEI can buffer the pH, causing 
the ATPase to transport more protons to reach the desired pH again. The accumulation 
of protons in the vesicle results in an influx of counter ions causing osmotic swelling 
and rupture of the endosomal membrane, and thus releasing of the PEI polyplexes into 
the cytoplasm.  
 
 
 
 
 
 
 
 
Although being known as the gold standard for plasmid delivery, PEI effectiveness as a 
vector for ONs is considered to be far less pronounced. This can be attributed to the 
weak electrostatic cohesion between the polymer and the relatively short ONs, which 
leads to rapid dissociation of the polyplexes at the anionic cell surface. Moreover, PEI 
is known to be toxic when used at high doses. This toxicity is associated with the high 
amount of positive charges that can cause membrane damage in cells and non-specific 
binding to serum proteins hence rapid clearance by RES before reaching their site of 
action (116). The non-biodegradability of the polycation is another factor causing its 
high toxicity. Therefore, modification of PEI and/or its incorporation into other 
polymers have been recently investigated for getting less toxic derivatives that can be 
used for efficient formulation and delivery of ONs.  
 
1.4.2.1 MODIFICATIONS IN PEI 
The relative simplicity in modifying PEI backbone has been exploited in order to 
generate delivery systems that are target-specific, less toxic and more efficient for short 
Nucleic acid
material Nucleic acid
material release
Figure 9. The proton sponge effect as a mechansim of endosomal escape by the polycation ”PEI”,
[Adapted from (109)]
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ONs. Amelioration of the strong positive charges of PEI, without reducing its “proton 
sponge” buffering capacity, has been the main goal in this polymer’s modification. 
Hydrophobic modification of PEI has been shown to improve cell membrane 
interactions for its formulation with siRNA. Recent studies demonstrated that attaching 
cholesterol to PEI backbone promoted siRNA stability in water-soluble lipopolyplexes 
and inhibited VEGF expression in vitro and induced tumor regression in vivo (117). 
Modification of branched PEI (25 KDa) by aliphatic lipids such as oleic and stearic 
acid resulted in better condensation and delivery of siRNA into melanoma cells 
(118,119). Modifying PEI with hydrophobic amino acids has also been reported to 
produce derivatives with marked efficiency in siRNA delivery into mammalian cells 
(120,121). In paper 1 of this thesis, PEI modified with the amino acid tyrosine, 
designated “PEIY”, was shown to form stable polyplexes with 2’-O-methyl SSO 
exerting high splice-correction efficiency in HeLa705 cells; a reporter model for β-
thalassemia described in the “Methods” section (122). Alternatively, introduction of 
negative charges into the polymer backbone has been shown to enhance the efficiency 
and biocompatibility of the polymer (123,124). Examples of the latter was the 
introduction of succinic acid groups into the backbone or acetylation of the amino 
groups, which resulted in more stable and less toxic polyplexes with siRNA. Reducing 
the surface charge of the polyplexes was also achieved via PEGylation (125,126). 
Successful trials using PEG-PEI copolymers for delivery of 2’-O-methyl SSOs in 
cultured cells and in mdx mice have been reported (127,128). 
 
The non-biodegradability of PEI (25KDa), also known as high molecular weight PEI, 
made scientists think about synthesizing degradable versions of PEI. Those versions 
mainly consist of low molecular weight (LMW) PEIs, linked via cross-linkers that can 
be easily removed inside the cells (129). PEIs in such form displayed much lower 
cytotoxicity as a result of their rapid in-situ degradation into small molecular weight 
water-soluble fragments, easily processed and removed by the cells. Interestingly, 
hydrophobic modification of the LMW PEI further improved the stability of siRNA 
polyplexes and hence resulted in better down-regulation efficiency (130).  
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1.4.3 CELL-PENETRATING PEPTIDES (CPPs) AS DELIVERY 
SYSTEMS. 
 
1.4.3.1 DISCOVERY AND TYPES OF CPPs 
The idea of using peptides as delivery systems came from the observation that some 
proteins, mainly transcription factors, could shuttle within the cell and from one cell to 
another. A more specific finding was reported in 1988 by two research groups that 
independently published results in the same CELL issue showing that both the 
recombinant and the chemically synthesized Tat protein (86 amino acids) were found to 
be rapidly taken up by the cells in tissue culture (131,132). Few years later, the 60 
amino acid homeodomain of the Antennapedia protein in Drosophila was also shown to 
penetrate cells (133). It was not until 1994 when the cell-penetrating capability could be 
achieved by a relatively short peptide sequence (16-mer) derived from the third helix of 
the homeodomain of the Antennapedia and termed “penetratin”(134) . This peptide and 
others such as: the 11-mer peptide derived from the HIV-1 tat protein, the 27-mer 
chimeric peptide termed “transportan”  and even simple polyarginines (R8)  were all 
shown to translocate across the plasma membrane and carry molecules along in this 
process (135). During the past few years several other CPPs have been discovered and 
studied as drug delivery vehicles, some of which are stated in (Table 2).  
 
 
 
 
 
 
 
 
 
 
According to the origin of the peptide, CPPs can be protein-derived such as tat and 
penetratin or chimeric such as transportan, TP10 and MPG or synthetic CPPs such as 
the polyarginines (136). CPPs in general can be defined as polybasic and/or 
amphipathic peptides, usually less than 30 amino acids in length that are internalized 
within most cell types. In fact, these peptides have recently attracted much interest as 
Table 2. Selection of CPPs and their sequences
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promising non-toxic delivery vectors for different kinds of therapeutics such as small 
drug molecules, proteins, plasmid DNA and ONs (135,137,138) .  
  
1.4.3.2 FORMULATION STRATEGIES OF ONs WITH CPPs 
Two main strategies have been used for attaching a CPP to its cargo: either via a 
covalent linkage or through the formation of a non-covalent complex. The covalent 
conjugation approach has been applied to link CPPs to various cargos. Absorption, 
distribution, tissue targeting and cellular uptake of many drug molecules such as anti-
cancers and anti-HIV have been improved via chemical conjugation to CPPs (139-141). 
In the field of ON-based pharmaceuticals, the covalent coupling of CPPs has been an 
advantageous route for delivery of uncharged nucleic acid analogues such as PMOs and 
PNAs. In dystrophin deficient mdx mice, PMOs chemically conjugated to  
polyarginine-based CPPs could accomplish high levels of splice-switching as shown by 
restoration of dystrophin protein to more than 50% of normal levels in all peripheral 
muscles (142). Moreover, an evidence of restored cardiac dystrophin protein was 
observed for the first time using those CPP-PMO conjugates (98,143). Oppositely, 
when naked PMOs were intravenously administered to mdx mice, although using high 
doses and a multiple-injection regimen, the splice-switching efficiency remained 
relatively low with high variations and no observed effect in the heart (144). PNA-
based ONs used for splice-switching have also been conjugated to CPPs resulting in 
high efficiency in many splice models such as the DMD model and the HeLa705 cells 
(145). However, coupling of CPPs, which are positively charged, to ONs made of 
negatively charged nucleic acids has not been as easy to achieve. This limitation plus 
the laborious procedures involved in the chemical conjugation led to the other approach 
of linking cargoes to CPPs: the non-covalent complexation. 
 
The non-covalent or co-incubation strategy is mainly based on the electrostatic 
interaction between the positively charged CPPs and the negatively charged nucleic 
acids. This strategy has many advantages such as avoiding the time-consuming 
chemical conjugation and subsequent purification procedures. Moreover, there is no 
limitation on the size of the ON and interestingly, it was found that lower 
concentrations of ONs are required to achieve a biological response. Non-covalent 
complexation was used for efficient delivery of siRNAs both in vitro and in vivo (146). 
The amphipathic MPG was the first CPP reported for successful delivery of siRNA 
targeting GAPDH mRNA after non-covalent complexation (147). Another study 
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showed that a small peptide derived from rabies virus glycoprotein (RVG) and attached 
to a polyarginine stretch successfully delivered antiviral siRNA into CNS of Japanese 
encephalitis virus-infected mice and prolonged their survival rate (148). Another 
interesting way for formulating siRNA to a CPP was through using a Tat fusion protein 
with an RNA binding domain (RBD). In that way the RBD domain is used as a 
molecular glue to attach the Tat peptides to the siRNA (149). This system promoted 
significant siRNA-mediated gene silencing in different primary cell cultures, however 
rather high siRNA concentrations were required. The non-covalent strategy has also 
been applied for the efficient delivery of SSOs made of 2’-O-methyl phosphorothioate 
nucleic acids (150). 
 
1.4.3.3 MODIFIED CPPs AND THE “PEPFECT” PEPTIDES 
CPPs are taken up primarily by endocytic pathways, and consequently the cargo is 
commonly retained in endosomes without reaching their site of action within the 
cellular machinery (135,151). This obstacle can be overcome in vitro using 
lysosomotropic strategies such as the photochemical internalization treatment or the 
addition of chloroquine. However, such approaches are not suitable for in vivo 
application. Therefore, several chemical modifications have been introduced to CPPs 
not only to enhance the endosomal escape and release of cargo but also to improve their 
membrane interaction and their formulation and transfection efficiency for ON-based 
drugs (152).  
 
 
 
 
 
 
 
 
 
 
 
 
 
CPP
Modified CPP
ON
endocytosis
endosomal
entrapment
endosomal
escape
nucleus
Biological effect of the ON
Figure 10.Schematic illustration showing the endocytotic uptake of ON/CPP complexes. Most internalized 
complexes remain entrapped in endosomal compartments, which greatly reduces the bioavailability of ONs. 
By introducing different chemical modifications, the release of ONs from endosomes is significantly enhanced, 
and thus increasing the biological response, [Adapted from (152)].
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One example is the development of a histidine-containing endosomolytic α-helical 
penetratin analogue, EB1, which was able to form complexes with siRNA and promote 
endosomal escape (153). Another way for avoiding the endosomal entrapments is the 
use of fusogenic peptides such as HA2 peptide and conjugate them to CPPs (154,155). 
C-terminal cysteamide modification in MPG and CADY peptides was shown to 
increase their membrane association and stabilize complex formation by the formation 
of peptide dimers (147,156). Cholesteryl modification of polyarginines was reported to 
enhance their efficiency for local delivery of siRNA targeting VEGF in mice bearing 
subcutaneous tumors (157). Modifying CPPs with lipophilic moieties such as fatty 
acids has also been employed to increase the bioavailability of non-covalent complexes 
of CPPs with ONs. The conjugation of decanoic acid moiety to Tat-PNA ONs 
conjugates significantly increased the splice-correction efficiency by the system (158). 
Stearylation of the amino acids in a CPP has been shown as another platform for 
improving the transfection efficiencies of many CPPs for delivery of siRNAs (159,160) 
and 2’-O-methyl PS-ONs (161). 
 
The PepFect (PF) series of CPPs (Table 3), developed by the Ülo Langel group, is 
based on the chemical modification of CPPs and important members of this series will 
be discussed here (162).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Starting from transportan 10 (TP10), N-terminal stearylation of TP10 produced stearyl 
TP10 known as PF3. Although being highly efficient for delivering plasmid DNA in 
PF6
Stearyl-AGYLLGKLLOOLAAAALOOLL-NH2PF14
PF5
Stearyl-AGYLLGKINLKALAALAKKIL- NH2Stearyl TP10 (PF3)
AGYLLGKINLKALAALAKKIL- NH2TP10
SequenceName
Table 3. Selected members 
from the PepFect series of CPPs
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cells and in mice (163), this peptide was shown to have a modest effect for delivery of 
short ONs such as SSOs in cell models and only in serum-free conditions (161,164). To 
further improve the endosomal escape efficiency, a trifluoromethylquinoline (QN) -
based derivative was conjugated to succinylated Lysine7 residue in TP10. This 
molecule is working as a proton sponge which would greatly improve the endocytic 
escape of the ON. This derivative, named as PF5, caused a high level of efficiency 
when used for delivery of siRNA into cell cultures (165). To further improve the 
stability, both the QN moiety and stearylation, previously used in PF3, were combined, 
generating the PF6 peptide. PF6 was shown to be highly active in delivery of siRNA 
into hard-to-transfect and primary cells with quite high tolerability to serum. More 
interestingly, in vivo gene down-regulation was achieved after systemic administration 
of siRNA formulated with PF6 (165). Another kind of modification in TP10 has led to 
the development of the new derivative PF14, which is characterized by the high 
stability in acid conditions, thus enabling the formulation of ON as an orally-
administered solid dosage form (166). PF14 is further discussed in paper 2 and 3 of the 
papers constituting this thesis. 
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2 AIMS 
 
This thesis describes the use of three different ON-based pharmaceuticals, which are: 
splice-switching ONs, siRNA and an antigene ON working via Watson-Crick mode of 
action. The studies included in this thesis collectively aimed at optimizing the 
formulation and design of these ONs in order to improve their delivery and 
pharmaceutical significance. More focus was put on the following specific areas: 
 
1- Testing the efficiency of four different modified versions of PEI for the 
formulation and delivery of splice-switching ONs in mammalian cells. 
2- Developing the new CPP “PF14” as a successful delivery system for splice-
switching ONs both in solution and as a solid formulation. 
3- Evaluating the efficiency of PF14 for formulation and delivery of siRNA in 
mammalian cells and assessing the gastric stability of its solid formulations.  
4- Studying the binding mechanism of the newly-developed antigene ON “Zorro-
LNA” and further optimizing its design. 
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3 METHODOLOGICAL CONSIDERATIONS 
Numerous methods were used during this work. In this section, many of them will be 
discussed with some theoretical aspects. 
 
3.1 SYNTHESIS 
3.1.1 SYNTHESIS OF DELIVERY VECTORS. 
In this thesis, polymer-based and peptide-based vectors were used for formulation and 
delivery of ONs. Here is briefly described the synthesis of those vectors. 
 
3.1.1.1 SYNTHESIS OF MODIFIED PEI DERIVATIVES 
In paper 1, the well-known polymer PEI was chemically modified with four different 
amino acids (Tyrosine (Y), Tryptophan (W), Phenylalanine (F) and Leucine (L)) in 
order to get potentially more efficient delivery vectors for SSOs. Branched 25 KDa PEI 
containing primary, secondary and tertiary amines in a ratio of 1:1:1 was modified to 
produce the new derivatives (PEIY, W, F and L). From a synthetic point of view, the 
chosen amino acids can be coupled to PEI-amines without destroying nucleic acid-
binding properties, because over the course of the reaction a cationic amine replaces the 
reacted one (120). Briefly, the primary amines were allowed to react fully with the 
esters of butyloxycarbonyl (Boc)-protected amino acids. Boc groups were removed 
with trifluoroacetic acid, followed by dialysis and finally gave the desired products, 
with R-amino acid contents of 30% per ethylenimine. PEIY and PEIW were also made 
with 20% substitution and compared to the ones with 30% modification. 
 
3.1.1.2 SYNTHESIS OF PF14 
PF14 is a newly developed stearylated CPP. We have used PF14 as a vector for 
formulation and delivery of SSO and siRNA in paper 2 and 3 respectively. The 
methodology known as “solid-phase peptide synthesis”, pioneered by Bruce Merrifield 
in 1963, has led to great advance in the peptide synthesis field (167). This methodology 
is based on anchoring the growing peptide chain onto an insoluble solid matrix 
followed by adding an N-terminally protected amino acid then de-protection and so on. 
This method is used for the synthesis of peptides, some polymers, DNA and RNA. 
After PF14 was synthesized, purification was performed by HPLC and the identity of 
the purified product was verified by analytical HPLC and by mass spectrometer.  
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3.1.2 SYNTHESIS OF SINGLE-STRANDED ZORRO-LNA 
Mixmer LNA/DNA ON strands (single-stranded Zorros) were synthesized by solid 
phase phosphoramidite chemistry on an automated DNA synthesizer in 1.0 mmol 
synthesis scale. To achieve strand polarity reversal, i.e. 3’-5’-5’-3’ syntheses, we used 
inverted DNA together with the standard DNA and LNA amidite building blocks, 
which are commercially available. The inverted LNA amidite building blocks (5’-
methyl-C and T derivatives) were synthesized using the recently published procedure 
by Madsen et al. (168). 
 
3.2 OLIOGONUCLEOTIDES FORMULATION AND 
PHYSICAL CHARACTERIZATION 
 
3.2.1 FORMULATION OF ON/VEHICLE NANOPARTICLES. 
In paper 1, we have formulated SSOs using modified PEIs as delivery vehicles. 
Formulations were prepared via equivolumetric mixing of SSO at the desired 
concentration with the PEI-derivative at different charge ratios (NH3+/PO4-) ranging 
from 5:1 to 40:1. Both the SSO and PEI-derivatives were first incubated separately in 
serum-free DMEM medium for 5 min, then they were mixed together and incubated for 
30 min at room temperature before transfection to cells or physical characterization. 
In paper 2 and 3, SSO or siRNA was mixed with PF14, using different molar ratios, in 
50 µl aqueous solution and incubated for 1 hour at room temperature. This was 
followed by addition of the 50 µl formulation to 450 µl cell medium with or without 
serum for cell experiments or for physical characterization. 
 
3.2.2 SOLID DISPERSION. 
In paper 2 and 3, we made use of the solid dispersion technique to test the possibility of 
formulating PF14 nanoparticles with SSO or siRNA into solid formulations. Solid 
dispersion is a pharmaceutical method commonly used to enhance the solubility of 
poorly soluble drugs by dispersing them in hydrophilic solid matrices (169). Since our 
nanoparticles were already water-soluble, this technique was used here to produce 
nanoparticles with uniform distribution over water-soluble excipients by solvent 
evaporation. Additively, it enabled us to obtain nanoparticles as a solid formulation, 
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which is considered to be the most stable, desirable and commonly used pharmaceutical 
dosage form. Briefly, PF14/ON nanoparticles were mixed with solutions of different 
excipients (mannitol, lactose or PEG 6000) at different concentrations. Then, solvent 
evaporation was performed by speed drying under elevated temperature (55-60 °C) and 
reduced pressure.  
  
3.2.4 PARTICLE SIZE MEASUREMENTS 
Particle size has always been shown to have a great effect on the efficiency of 
pharmaceutical formulations. In this thesis, two different methods were used for 
assessing the particle size. 
 
3.2.4.1 DYNAMIC LIGHT SCATTERING (DLS) 
DLS is a well-established technique for measuring the size of molecules and particles 
typically in the submicron region. Particles in a dispersion system undergo Brownian 
motion, which is induced by the bombardment by solvent molecules that are moving 
due to their thermal energy. If the particles are illuminated by a laser, the intensity of 
the scattered light will fluctuate at a rate that is dependent upon the size of the particles. 
Analysis of these intensity fluctuations yields the velocity of the Brownian motion and 
hence the particle size using the Stokes-Einstein equation. The diameter that is 
measured in DLS is called the “hydrodynamic diameter” and refers to how a particle 
diffuses within a fluid. This method assumes that the particles are spherical. 
Measurements are affected not only by the particle core but also by the surface 
structure and the concentration and type of ions in the solution. In paper 1 and 2, DLS 
studies were conducted using a Zetasizer Nano ZS apparatus (Malvern). Formulations 
were diluted in OptiMEM® cell culture medium supplemented with 10% fetal bovine 
serum (FBS) before measurements. Samples were assessed in disposable low-volume 
cuvettes. All data was converted to ‘relative intensity’ plots from where the mean 
hydrodynamic diameter was derived. 
 
3.2.4.2 NANOPARTICLE TRACKING ANALYSIS (NTA) 
NTA is a recently developed technique which allows the tracking of the Brownian 
motion of nanoparticles in liquid suspension on a particle-by-particle basis. Similar to 
DLS, NTA measures the Brownian motion of nanoparticles and relate it to particle size 
through the Stokes-Einstein equation. In contrast to DLS, the Brownian motion is 
analyzed by visualizing and tracking positional changes of each individual particle in 
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two dimensions from which the particle diffusion and then the hydrodynamic diameter 
can be determined. For the analysis of poly-disperse samples or those which contain 
different particle types of differing refractive index, the NTA approach is far better 
suited due to its particle-by-particle measurement (170). Because DLS is an ensemble 
measurement, which is significantly biased to larger, higher scattering particles, the 
resulting intensity-weighted average can be seriously misleading in the analysis of 
poly-disperse samples. In paper 3, NTA studies were conducted using the nanosight 
LM-10HS machine equipped with a sample chamber with a 405 nm laser. Briefly, 0.5 
ml of each sample was injected in the sample chamber using disposable syringes. The 
samples were measured for 40 s with manual shutter and gain adjustments. Both size 
and concentration of the nanoparticles in each sample was measured by the machine 
and a 10 sec video clip file showing the particles moving under Brownian motion was 
taken for each sample.  
 
3.2.5 ZETA POTENTIAL  
The particles in a dispersion system have a surface charge resulting from the ionization 
of surface groups or the adsorption of charged species present in the system. The 
development of that charge affects the distribution of ions in the surrounding interfacial 
region, resulting in an increased concentration of strongly bound counter ions close to 
particle surface forming a first layer known as “Stern layer”. Being strongly attached, it 
moves together with the particles in the medium. Then, a second layer of ions and 
counter-ions is formed, which is less strongly bound to the suspended particle. This 
layer is in direct contact with the bulk of the dispersion system and is known as 
“diffusion layer”.  Thus an electrical double layer is formed around each particle and 
the potential difference across this double layer is called “zeta potential” (Figure 11) 
(171). In fact, the magnitude of the zeta potential gives an indication of the potential 
stability of the colloidal system. Large positive or large negative zeta potential means 
that there will be enough repulsion between the particles and thus no tendency for 
aggregation in the system. Oppositely, particles will easily flocculate if they have low 
negative or low positive or neutral zeta potential. Zeta potential is determined by 
electrophoresis of the sample and measuring the velocity of the particles using laser 
Doppler velocimetry. It is highly sensitive to the amount and type of ions in the 
suspension and its pH. In paper 2, zeta potential of PF14 formulations with SSO was 
measured in a single use folded capillary cell using the Zetasizer Nano ZS apparatus. It 
was conducted in a flow cell chamber using the DelsaNano-c (Beckman Coulter) in 
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paper 3. Measurements were performed in different suspending media: water, 
OptiMEM® or 0.01mM KCl.  
 
 
 
 
 
 
 
 
 
 
3.2.6 POLYANION COMPETITION ASSAY FOR ASSESSING 
THE POLYPLEXES STABILITY  
One way to measure the relative stability of ON polyplexes is to add a polyanionic 
compound (such as heparin) which can compete with the positively charged polymer 
and release the ON from the formulation. The stability of the polyplex is higher when 
increased concentrations of the competing anion are required. For the polyplex to be 
ideal, it needs to have an intermediate profile when tested by this method. This means 
that it should be stable enough to protect the cargo from degradation but not too stable 
to allow the successful release of the ON to exert its effect. In paper 1, Polyplexes of 
SSO with PEI or its amino acid modified derivatives were prepared in 20:1 ratio and 
were incubated for 15 min at 37 °C in the presence of heparin sodium over a range of 
concentrations. Samples were then analyzed on 1.5% agarose gels and the bands were 
visualized by staining with SYBR green II.  
 
3.2.7 ACCELERATED STABILITY TESTING FOR SOLID 
FORMULATIONS 
Accelerated stability testing is routinely used to assess the long-term stability of 
pharmaceutical formulations. In this kind of testing, the formulations are subjected to 
drastic conditions like high temperature for long time periods. Storage at high 
temperatures increases the rate of degradation reactions that could take years to occur 
(172,173). In paper 2, solid formulations of PF14/SSO prepared with lactose at a 
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concentration of 3.33% were stored either at room temperature or in ovens of adjusted 
temperatures (40 or 60 °C). Stored formulations were monitored for 8 weeks. Samples 
were taken at 0, 2, 4 and 8 weeks time-points and then tested for their efficiency in cell 
culture. 
 
3.2.8 ASSESSMENT OF SOLID FORMULATIONS STABILITY IN 
SIMULATED GASTRIC CONDITIONS 
One of the great obstacles confronting solid formulations is their stability in gastric 
conditions. In paper 3, we have challenged mannitol solid dispersions of siRNA/ PF14 
nanoparticles by incubating them in simulated gastric fluid (SGF) prepared according 
to the European Pharmacopeia with and without pepsin for 30 minutes. After treatment, 
the mixtures were either added to cells to verify the efficiency of siRNA in the 
formulations or analyzed by the NTA system to assess the particle size 
 
3.3 EVALUATION OF FORMULATIONS IN MAMMALIAN 
CELL CULTURE 
Cell and tissue culture models, also known also as (in vitro testing), are considered 
indispensible tools to test the efficiency and toxicity of newly developed drugs. While it 
can never fully replace animals used for medical testing, it can still help reduce their 
use. It is relatively low-cost, less cumbersome and it provides researchers with 
information specifically related to humans. In this thesis, we have used several cell 
lines to evaluate the efficiency and toxicity of the developed ON-based 
pharmaceuticals. 
 
3.3.1 CULTURING OF THE CELL LINES 
HeLa705, BHK-21 luc, HEK293 luc and HUH7 cell lines were grown in DMEM 
medium with glutamax and supplemented with 10 % FBS. Cells were maintained at 
37 °C, 5% CO2 in humidified incubators. One day prior to transfections, cells were 
seeded at 50,000 cells per well in a 24-well plate. The H2K mdx myoblasts were 
grown at 33 °C under a 10% CO2/ 90% air atmosphere in high-glucose DMEM 
supplemented with 20 % FBS, 0.5% chicken embryo extract.  Mdx mouse myotubes 
were obtained from confluent H2K mdx cells seeded in gelatin-coated 24-well plates 
following 2 days of serum deprivation (DMEM with 5% horse serum) and incubation 
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at 37 °C under 5% CO2. The myotube development was monitored by light 
microscopy. 
 
3.3.2 SPLICE-SWITCHING MODELS AND ASSAYS 
One of the aims of this thesis was to optimize vectors for successful delivery of the 
antisense splice-switching ONs. For their assessment, we have used two cell lines 
representing models of two diseases caused by aberrant splicing.  
 
3.3.2.1 HeLa705 (A REPORTER MODEL FOR β-THALASSEMIA DISEASE) 
HeLa705 are cells stably transfected with a luciferase gene in which the coding region 
is interrupted by a mutated β-globin intron which results in defective splicing and 
aberrant luciferase protein (174). Masking the mutated splice site by antisense SSO 
redirects splicing towards the correct mRNA and thus to the corrected luciferase 
protein. Splice-correction was measured on both the protein and mRNA levels.  
 
 
 
 
 
 
 
 
 
For analysis of the luciferase protein, cells were harvested in Reporter lysis buffer. The 
protein activity was assessed using luciferase reagent (Promgea) and monitored in 
Fluostar optima (in paper 1) and in GLOMAX 96 microplate luminometer (in paper 2). 
For analyzing the corrected luciferase mRNA levels, cells were trypsinized, total RNA 
was isolated from the cell pellets and RT-PCR was performed. The PCR products were 
analyzed in a 2% agarose gel in 1x TBE buffer and visualized by SYBR Gold staining. 
Splice-correction efficiency was calculated as the % of the corrected luciferase band to 
the sum of the corrected and the aberrant bands. 
 
3.3.2.2 Mdx MOUSE MYOTUBES (A MODEL FOR DMD DISEASE) 
Mdx mouse myotubes were obtained from confluent H2K mdx cells, which is a 
myogenic cell line derived from transgenic mice carrying a point mutation in exon 23 
SSO
Protein mRNA
Figure 12. HeLa705 cells as a model for splice-switching. 
The mutation can be masked by SSO leading to the production 
of corrected luciferase, which can be measured both 
on the protein and mRNA levels.
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of the dystrophin gene (175). Thus, this cell line serves as the leading cell-model 
system for development of drugs used for DMD treatment. Masking the point mutation 
in exon 23 leads to skipping of the whole exon and production of shorter, partially-
functional dystrophin mRNA. In paper 2, PF14/SSO nanoparticles were transfected 
into mdx mice myotubes. RNA was isolated and RT-PCR was performed. The exon-
skipping efficiency was calculated as the percentage of the exon-skipping band to the 
sum of the exon-skipping and the full length bands. 
 
3.3.3 RNAi ASSAYS 
For the evaluation of the efficiency of siRNA/PF14 formulations in paper 3, we used 
two different approaches. First, we used reporter cell lines stably expressing luciferase, 
transfected them with luciferase siRNA formulated by PF14 and then measured the 
down-regulation in luciferase expression. The reporter cells used were:  BHK-21 and 
HEK 293 cell lines, both stably transfected with luciferase gene. Luciferase expression 
was measured, as stated earlier, in the “splice-switching assays” section. Secondly, we 
investigated the targeting of an endogenous gene that is normally expressed in 
mammalian cells. We transfected HUH7 cells with hypoxanthine-guanine 
phosphoribosyl transferase (HPRT1) siRNA formulated with PF14 at different 
concentrations and measured the effect at different time points. HPRT1 gene was 
selected, since its protein has a long cellular half-life (around 48 hrs) so the down-
regulation will have a minimal impact on the vitality of the transfected cells. We 
measured the silencing of HPRT1 on the mRNA level using real-time PCR. 
 
3.3.3.1 REAL-TIME MULTIPLEX REVERSE TRANSCRIPTASE PCR  
When it comes to both detection and quantification of gene down-regulation, real-time 
(also known as quantitative) PCR is the most robust method to do it. In paper 3, we 
optimized a multiplex real-time PCR allowing both quantification and reliable 
normalization of the target gene level to the reference gene level in one step. In the 
same step, the reverse transcription reaction was also included, thus, further increasing 
the accuracy and minimizing the error. Using this method, isolated RNA was analyzed 
to amplify HPRT1 (target gene) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (reference gene). The assay was performed using the Quantifast® Multiplex 
RT-PCR kit. Data were analyzed by the ∆∆Ct method using the StepOne® software 
version 2.2. Standard curves were made for both genes using known amount of RNA 
   35 
and serially diluted in order to confirm the efficiency of PCR which was always about 
100%.  
 
3.3.4 TOXICOLOGICAL TESTING OF THE FORMULATIONS 
Assessment of the potential toxicity of new pharmaceuticals is a quite crucial step 
usually done in the early phases of drug development (176). Regarding the field of 
biologic pharmaceuticals, many of the commercial transfection reagents, although 
showing high efficiency for cell transfection, still have a poor safety and 
biocompatibility profiles limiting their use for in vivo delivery. Cell-based toxicity 
assays are usually used for screening of drugs and from their results human toxicity 
can be predicted (177). These assays are based on different mechanisms of action and 
they evaluate the toxicity of the drug by measuring its response on a specific cellular 
process or pathway. In this thesis, two different methods were used for toxicity 
assessment.   
 
3.3.4.1 WST ASSAY 
In this assay, cell toxicity is directly correlated to the amount of formazan dye formed 
as a result from the cleavage of tetrazolium salts by mitochondrial dehydrogenase. 
Thus, healthy, metabolically active cells have more active enzymes and thus produce 
more formazan dye which is quantified spectrophotometrically. This method was 
performed, in paper 1 and 2, according to the manufacturer protocol to assess the 
cytotoxicity of the different formulations. Briefly, cells were seeded in 96-well plates in 
DMEM medium with 10% FBS 24 hrs before transfection. Cells were treated with the 
ON/vehicle formulations or with the vehicle alone at different concentrations in serum-
free medium for 4 hours followed by addition of medium with 10% serum for 
additional 20 hrs. WST reagent was added according to the protocol and then 
absorbance was measured at 450 nm. The percentage of viable cells was determined by 
normalizing the values obtained for treated cells with untreated cells.  
WST has many advantages compared to other reagents in the family of tetrazolium 
salts such as the well-known reagent MTT. It is soluble in culture medium, more stable, 
has a wider linear range and shows accelerated color development. However, this kind 
of assay, including WST, is a single-point analysis. It also suffers from the lack of 
quality control when it is used to determine cell viability before and after treatment. 
These drawbacks are avoided in the newly-developed “XCELLigence” system. 
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3.3.4.2 XCELLigence ASSAY 
This system utilizes an electronic readout called “impedance” to non-invasively 
quantify adherent cell proliferation and viability in real time. The cells are seeded in 
standard microtiter plates that contain microelectronic sensor arrays. The interaction of 
cells with the electronic biosensors generates a cell-electrode impedance response, 
which indicates cell viability and also correlates with the number of cells seeded in the 
well. Therefore, this system allows real-time, rather than end point, measurement of 
cell proliferation, viability and cytotoxicity. PEIY alone and PEIY/ON formulations in 
paper 1 were evaluated for their cytotoxicity using this system according to the 
manufacturer’s protocol. Briefly, cells were seeded in E-plate and cultured for 20 hrs at 
37 °C, 5% CO2, before the addition of the treatments. Changes in the cell status were 
monitored and quantified by detecting sensor electrical impedance every 15 min during 
45 hrs. 
 
3.4 S1 NUCLEASE DIGESTION 
This method was used in paper 4 as a technique to assess the double-strand invasion 
(DSI) efficiency by Zorro-LNA constructs. S1 nuclease is an enzyme that is known to 
cleave single-stranded (ss) stretches in ds DNA. Since the binding of Zorro-LNA to ds 
DNA occurs via DSI, this should create ss stretches that will be accessible to cleavage 
by the enzyme. While S1 nuclease is specific for cutting ss DNA, it might still cause 
unspecific nicking and degradation of supercoiled ds DNA under non-optimized 
conditions. Therefore, in this paper, we adjusted the concentrations and conditions in 
order to preferentially allow for the specific activity of the enzyme.  
 
 
 
 
 
 
 
 
Briefly, 0.5 µg of plasmid hybridized with different Zorro constructs or with linear 
LNA/DNA ONs was digested by 8.3 units of S1 nuclease in 1x S1 nuclease enzyme 
+ +
+
Linear plasmid
Nicked plasmid
Figure 13. Schematic illustration of how Zorro 
double-strand invasion will create single-stranded 
stretches of DNA susceptible to S1 nuclease digestion. 
As shown by the arrows, the enzyme action will lead 
to an increase in the nicked plasmid form and/or to 
a production of the linear form of the plasmid.
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buffer. The incubation was done for 4.5 min on ice and the reaction was stopped by 
adding EDTA to concentration of 77 mM. Samples from the digestion mixtures were 
analyzed on 0.9% agarose gels and visualized by SYBR® Gold staining. After 
quantification of the super-coiled, nicked and linear fragments bands, DSI efficiency 
was calculated based on the ratio between the super-coiled plasmid band and the sum 
of all bands. DSI C50 and DSI t50, which correspond to the concentration (DSI C50) of 
the Zorro construct and the time (DSI t50) at which 50% DSI happens, were calculated. 
We used these parameters to compare the DSI efficiency of the different Zorro 
constructs. 
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4 RESULTS, DISCUSSION AND PERSPECTIVES 
 
4.1 Formulation and delivery of antisense ONs by modified PEIs 
 
PEI is a well-known polymer that has been the focus of an increasing interest in the 
study of gene delivery (113,178). PEI is a polymer with a high positive charge density 
and a high intrinsic endosomolytic activity due to a strong buffer capacity in the pH 
range between 5 and 7.5 (proton sponge mechanism) (179). Although PEI is known as 
the gold standard as a plasmid DNA carrier, its effectiveness in ON delivery is 
considered to be far less pronounced (180). The reason behind that is the short length of 
ONs, which makes the electrostatic cohesion between the polymer and nucleic acids 
not strong enough, thus, leading to unstable formulations that easily dissociate at the 
anionic cell surface. Besides, PEI has toxicity considerations limiting its use for all 
kinds of nucleic acid delivery. 
 
In this paper, we have modified the commercially available branched 25 KDa PEI with 
four natural amino acids to produce four derivatives of PEI namely: PEIY, PEIW, PEF 
and PEIL. We thought that by incorporating hydrophobic amino acids, the polymers 
would gain a self assembly property, which in turn would enhance the binding 
efficiency to short ONs. Moreover, these amino acids constitute the core of globular 
proteins and help maintain protein structure, which would be beneficial in ameliorating 
the known toxicity of PEI. Finally, we wanted to test these modified PEIs for the 
formulation and delivery of antisense splice-correction ON, abbreviated in this paper as 
(ASO), and compare it to what was reported for siRNA delivery. In other words, we 
wanted to investigate if  siRNA (double-stranded, non-modified RNA bases, target site 
is in the cytoplasm) and ASO (single stranded, 2’-O-methyl with PS modified RNA 
bases, target site is in the nucleus) would behave the same when formulated and 
delivered into cells using the PEI-derivatives. 
 
DLS studies revealed that both PEIY and PEIW had self-assembly properties, since 
they could form particles in the absence of the ASO. However, PEIY formed 
significantly smaller particles with ASO than particles of ASO with PEIW and PEIF. 
This correlates with many recent reports, which show that providing PEI with mild 
hydrophobic properties would endow it with the ability to self-assemble, thereby 
stabilizing the formulation with siRNA (118,120,123). 
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 Interestingly, these modifications in PEI caused a dramatic change in the stability of 
ASO complexes and resulted in polymers with varied cohesive properties as assessed 
by the polyanion competition assay. PEIW and PEIF complexes with ASO, upon 
challenging with heparin, showed very slow release profiles (resistant shell-like 
particles), whereas with PEIL and the unmodified PEI, the ASO release rate was too 
fast (quite unstable formulations). This instability was also shown by the DLS studies, 
where the complexes completely dissociated upon addition of serum-containing 
medium. Interestingly, PEIY showed an intermediate profile suggesting that the 
binding was strong enough to protect ASO, but not too tight so it allowed its release to 
exert the desired effect. 
 
Similar to the study by Creusat G. et al (120), PEIY was the derivative that resulted in 
the highest activity and it significantly enhanced ASO delivery. ASO formulated with 
PEIY at charge ratio 20:1, or higher, induced 80% splice-correction on the mRNA level 
in the HeLa705 cells. This correction was significantly higher than that showed by 
ASO formulated with the commercial lipid-based transfection reagent Lipofectamine® 
and also exceeded the values measured in other reports using the same cell-model (181-
184). Moreover, extremely low doses of ASO (25 nM) still showed significant splice 
correction; 47% on the mRNA level. When the tyrosine content of PEIY (30% 
tyrosine/ethylenimine unit) was decreased to 20%, its efficiency was significantly 
diminished. This indicates that the efficacy of PEIY is also dependent on the degree of 
tyrosine modification, indicating the importance of keeping a certain 
hydrophobic/hydrophilic balance for the effectiveness of this polymer. 
 
The other PEI-derivatives were completely inactive for ASO delivery. This can be 
explained by either the too tight cohesion, which resulted in un-breakable particles (as 
in the case of PEIW, PEIF) or the weak stability making the particles rapidly dissociate 
upon contact with the cell surface anions (as in the case of PEIL). Oppositely, when 
assessed for delivery of siRNA, PEIW and PEIF were shown to be relatively active 
(120). In that study, PEIW became even more efficient when the tryptophan content 
was decreased to 20 %. However, the same reduction in the amino acid content did not 
improve the capacity of PEIW to deliver ASO. 
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PEIY was not toxic at the doses that showed significant splice-correction efficiency as 
measured by WST and XCELLigence cytotoxicity assays. If higher concentrations are 
required for in vivo applications for instance, potential cytotoxic effects must be 
considered. Inclusion of PEG to unmodified PEI and other polymer-based delivery 
systems has shown improvement in their in vivo performance and helped reducing their 
toxicity (185-187). Similarly, this approach can be used in the future to further optimize 
PEIY for in vivo delivery of short ONs. 
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4.2 Delivery of SSOs by PF14 and solid formulation development 
CPPs constitute very promising tools for in vitro and in vivo delivery of different types 
of cargo such as small chemical molecules, nucleic acids and proteins with quite low 
associated toxicity (135). Endocytosis is the mechanism by which CPPs are thought to 
utilize for cell internalization. However, one limitation has been their extensive 
entrapment inside endosomal vesicles. In this paper, we present a new chemically 
modified CPP, PF14, which builds on previous series of CPPs. Starting from stearyl 
TP10, we utilized ornithines as the main source of positive charges instead of lysines. 
The reason behind that exchange was based on earlier reports showing that poly-L-
ornithine demonstrated superior transfection efficiency (up to 10-fold) compared to 
equivalent poly-L-lysine systems. Furthermore, we hypothesized that ornithine, as a 
non-standard amino acid, would be less prone to serum proteases, and, thus, could 
retain the activity in serum conditions. 
 
We used PF14 to formulate SSOs targeting splice-site mutations in two cell-line 
models: HeLa705 cells and mdx mouse myotubes. Robust splice-switching was 
observed in both cell lines in both serum-containing and serum-free conditions and in a 
dose-dependant manner. At certain molar ratios, PF14 significantly exceeded the 
activity of Lipofectamine 2000® without associated toxicity as measured by WST 
assay. Interestingly, SSO formulated with PF14 elicited a fast onset of splice-switching 
activity as early as 8 hours. 
 
Uptake of PF14 complexes with SSO was attributed to endocytosis. When we 
performed transfections in presence of chloroquine, it showed an increase in the splice- 
switching activity while SSO uptake remained nearly unchanged. The endocytosis 
mechanism was confirmed by the extensive co-localization of the formulations with 
labeled dextran; a marker for fluid phase endocytosis. 
 
Then, we wanted to take our delivery system a step further by developing a suitable 
formulation for administration, more specifically, a solid dosage form, which is 
considered to be the most widely used form in several pharmaceuticals. We applied the 
solid dispersion technique by mixing the nanoparticles in suspension with excipient 
solutions then drying at relatively high temperatures (55-60 °C) under vacuum. The 
difference in type and concentration of the excipients had a huge impact on the activity 
of the formulation, with “3.33% lactose” being the one that showed splice-switching 
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activity nearly identical to the freshly prepared nanoparticles in solution. When the 
same method using the same excipients was applied to Lipofecatmine 2000® 
formulations, we found that they completely lost splice-switching activity. 
 
In order to assure the presence of intact particles after the formulation procedure, DLS 
studies were performed comparing the freshly prepared nanoparticles to the solid 
formulations. We found that the formulation which mediated the highest splice-
switching activity had particle size and particle size distribution most similar to the 
freshly prepared nanoparticles. Zeta potential measured for the nanoparticles in fresh 
formulation, or after solid dispersion, had negative values. In fact, this finding raises 
some interesting questions regarding the mechanism of the internalization and uptake 
of the particles. In theory, particles with negative surface charge will be repelled by the 
cell membrane negative potential. However, a previously reported CPP of the PepFect 
series designated “PF6” showed the same behavior (165). Other reports have also 
shown that cationic liposome complexes with plasmid DNA are negatively charged 
under optimal transfection conditions. A very recent study on the uptake mechanism of 
PF14/SSO nanoparticles has been performed (188). In that study, PF14 uptake has been 
shown to occur via “class A scavenger receptors”, a kind of receptors that mediate the 
uptake of LDL and many polyanioinic ligands. 
 
Finally, we have run an accelerated stability testing to the best formulation. The study 
revealed that PF14/SSO solid formulation had an excellent stability profile where no 
statistically significant loss in splice-switching efficiency was seen at any time-point 
except for 60 °C after 8 weeks, where the efficiency decreased to 70% of the initial 
value. Compared to lyophilized lipoplexes (172), PF14 solid formulation without 
further additives is considered to have an excellent stability profile. Studies in the 
future may be performed to further optimize the solid dispersion process through usage 
of other kinds of excipients and other additives that can improve the physical and 
biological properties of such formulations.  
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4.3 Development of acid-stable solid formulations of siRNA with PF14 
The newly developed CPP, PF14 has shown efficiency in formulation and delivery of 
SSOs both as solution and as solid formulation. In this paper, we aimed to evaluate the 
efficiency of the same peptide for formulation of a different kind of ON-therapeutics, 
namely siRNAs, using the non-covalent complexation strategy. More importantly, we 
wanted to test the stability of siRNA/PF14 solid formulations in simulated gastric 
conditions.  
 
First, we used PF14 to formulate siRNA targeting luciferase in HEK 293 and BHK-21 
cell-lines stably transfected with luciferase gene. In serum-containing medium, 
PF14/siRNA nanocomplexes at molar ratio 40 mediated more than 90 % knock-down 
utilizing 100 nM of siRNA. This shows that PF14 can efficiently deliver siRNA and 
provide sufficient stability against serum enzymes. In order to challenge the system for 
a more natural application, we assessed the blocking on the mRNA level of HPRT1, as 
an endogenous gene, in HUH7 cells. In dose-response experiments, the concentration at 
which 50% of HPRT1 mRNA was depleted (EC50) was 12 nM in serum-containing 
conditions. This low EC50 value indicates the high efficiency of siRNA/PF14 
nanoparticles compared to many other delivery systems. Concerning kinetics, PF14 
formulations at 50 nM dose of siRNA showed extremely rapid onset of action since the 
decrease in HPRT1 mRNA reached 70% after only 2 hours. This effect was 
significantly higher than that obtained by the well-known transfection reagent 
Lipofectamine RNAimax®. Moreover, down-regulation of HPRT1 mRNA lasted for 4 
days, which was the last time-point checked in the experiments.  
 
Similar to the PF14/SSO paper, the solid dispersion technique was herein used for 
drying PF14/siRNA nanoparticles into solid formulation. Upon screening several 
excipients using different concentrations, mannitol at the final concentration of 5% was 
the most optimal. To assure the stability of the nanoparticles after the relatively harsh 
solid dispersion technique, particle size analysis was performed using the NTA 
technique. Both measuring the particle concentration and visualizing particles under the 
Brownian motion are two advantages of the recently developed technique that further 
confirmed the stability of the formulations. There was no significant difference between 
the particle size of the freshly prepared formulation and the one as solid dispersion, 
both showed particle size mean of about 120 nm when measured in OptiMEM® 
medium with 10% FBS. This obviously assures the stability of the particles after the 
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speed-drying procedure. To determine the surface properties of the particles, zeta 
potential was measured both in water and in OptiMEM®. When resuspended in water, 
the nanoparticles showed a positive zeta potential (22.74 mV). However, when 
resuspended in OptiMEM®, it was reversed to negative values (-12.98 mV). It is well 
known that the zeta potential is highly sensitive to the amount and type of ions in the 
suspension. The net negative charge of the nancomplexes implies that they may recruit 
the same pathway as that recently reported for those of PF14 with SSO; via class A 
scavenger receptors (188).  Similarly, a part of the siRNA cargo could be displayed on 
the particle surface at high local concentration enabling such interaction.  
 
Since stability against degradation by the gastric fluid is a crucial factor that affects the 
bioavailability of drugs after oral administration, PF14/siRNA solid formulations were 
assessed for such stability. Interestingly, the formulations retained most of their RNAi 
activity after 30 min incubations in SGF with or without pepsin. When the incubations 
were performed for longer time periods, the activity was kept the same in the case of 
SGF incubations with slight decrease in efficiency in the presence of pepsin. This 
indicates that PF14 effectively protects the encapsulated siRNA from the gastric 
acidity. The decrease in activity is not surprising for such plain formulation and can be 
further addressed in the future by other formulation strategies such as coating.
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4.4 Zorro-LNA antigene ON: mechanism of binding and design    
optimization 
Zorro-LNA (Zorro) is an antigene ON that was first developed by our group (73,74). 
The first generation of Zorros (designated 2-ON Zorros) is formed of two LNA/DNA 
mixmer ONs that are annealed together via complementarity in a 7-nucleotide (7-nt) 
linker to make a Z-shaped ON. At the first stage of its development, Zorro was 
hypothesized to strand-invade into duplex DNA, thus binding to the two strands of 
DNA via Watson-Crick mode of binding but this was never formally proven. In this 
paper, our first aim was to experimentally prove that Zorro binds by double-strand 
invasion (DSI) into duplex DNA.  
 
In fact, avoiding intra-molecular binding between bases in the linker region and bases 
in the arms remained an obstacle, making the design of the first-generation Zorro-
LNAs a cumbersome process. Moreover, similar to siRNAs a pre-annealing step was 
required for the hybridization of the two ONs in order to generate the complete Zorro 
construct. For an ON-based pharmaceutical, the design should ideally be simple and 
predictable. Therefore, to make the processes more straightforward, we thought about 
making the Zorro in the form of a single-ON entity, single-stranded Zorro (ssZorro). In 
addition, from a size point of view, ssZorro would be smaller than the original 2-ON 
Zorro. It is well established that small-sized LNA-based pharmaceuticals are more 
efficient (189). A functional ssZorro would therefore presumably also facilitate its 
formulation and delivery. 
 
Starting with the first aim of the paper (proving DSI as a mechanism for Zorro-binding 
to duplex DNA), we made use of S1 nuclease; a restriction enzyme that specifically 
cuts ss DNA stretches. The digestion conditions were optimized to obtain robust 
digestion of a plasmid hybridized to the well-known double-strand invader, bisPNA (as 
a positive control), without any significant digestion of a plasmid hybridized to a TFO 
(as a negative control). Target plasmid pN25-2BS hybridized with different 
concentrations of Zorro-LNA showed pronounced digestion by S1 nuclease, while both 
the mock-treated plasmid and the one devoid of Zorro target sites (pN25-0BS) did not. 
A second plasmid with a different target site (pN25-tyr), hybridized to different 
concentrations of the corresponding Zorro showed the same degree of S1 nuclease 
sensitivity as the hybridized pN25-2BS plasmid. These results clearly suggest that 
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Zorro-LNAs indeed are able to strand invade into ds DNA without sequence 
restrictions. 
 
Then, we proceeded to the second aim of the paper, which was the synthesis of ssZorro 
construct and comparing its DSI efficiency to the original 2-ON Zorro. To investigate if 
keeping the linker in a double-stranded (ds) form, i.e. in a more rigid form, is required 
for maintaining the DSI property, we also made a 7-mer LNA-DNA ON (stiffener) to 
bind to the ssZorro in the linker region. Interestingly, we found that ssZorro is 
significantly more efficient in DSI into the corresponding target site in the plasmid 
DNA than 2-ON Zorro. The rigidity does not seem to be of value when it comes to the 
DSI since the ssZorro without a stiffener gave better results than the one with. 
 
 We went one step further by testing the use of other types of linkers than the 7-nt based 
one i.e. using chemical-based linkers. Application of non-nucleotide linkers has been 
previously investigated in many ON-based approaches and bioconjugation of ONs with 
polymers is widely used for improving cell penetration and stability (190,191). 
Therefore, we synthesized eight ssZorro constructs with eight different chemical linkers 
that vary in length and hydrophilicity. PEG-based linkers used in the study and the 
alkyl-chain linker with intermediate length showed prominent DSI. However, the 
longest alkyl-chain linker (C12 x 3), although having the highest degree of flexibility, 
showed very poor DSI ability. This could be explained by the hydrophobicity, which 
could increase aggregation, thereby making this construct less available for strand 
invasion. Moreover, the flexibility may lead to that the other ON is not ideally 
positioned for DSI. Since we believe that the smaller the size of the ssZorro, the more 
feasible will be its formulation and delivery, we also investigated the possibility of 
using a linker-less construct. Although the later displayed reduced DSI C50 and t50 
values, it eventually reached a high plateau level of DSI, similar to that of the ssZorro 
with the 7-nt linker. This shows that strand invasion of ds DNA can be achieved, using 
the smallest (32 nt in length) of all tested Zorros. 
 
To summarize, in this report we have proven DSI as the way by which Zorro binds to 
duplex DNA. ssZorro was shown to be better in DSI than the original 2-ON Zorro. The 
composition of the linker could be important for future therapeutic considerations. For 
future perspectives, we are in the phase of making efficient formulations of Zorro-LNA 
that can successfully deliver it to the nucleus to exert its action. We are choosing 
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therapeutic target sites so Zorro technology can be applied for treatment of disease 
models starting with mammalian cells and then proceeding to in vivo animal studies. 
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